Hepatocyte growth factor ( HGF ) is involved in malignant behavior of cancers as a mediator of tumor-stromal interactions, facilitating tumor invasion and metastasis. We have investigated whether a blockade of HGF using recombinant NK4, an HGF antagonist, would lead to growth inhibition of the human gastric carcinoma cell line, TMK1. To evaluate the function of endogenous NK4 and investigate its potential inhibitory effect, TMK1 cells were transfected with NK4 plasmid. After selection, NK4-expressing cells ( T11 ) were obtained, and cell growth was evaluated. Significant growth inhibition was observed in the T11-group compared to the control both in vitro and in vivo. Moreover, we investigated the effect of exogenous NK4 transferred by an adenovirus vector ( AdCMV.NK4 ). Cell proliferation of AdCMV.NK4 infected TMK1 cells was significantly inhibited compared with the control group. We also assessed the in vivo tumor suppression effect of AdCMV.NK4. The tumor volume following treatment with AdCMV.NK4 was significantly inhibited compared to that of the control group. These findings indicate that NK4 gene expression has a potential role in controlling proliferation of cancer cells. In conclusion, NK4 is a promising therapeutic agent and its gene delivery may be a new approach to treating patients with advanced gastric cancer.
A lthough increased detection of early gastric cancer, progress in surgical treatment, and a combination of adjuvant chemotherapies have improved the mortality of gastric cancer, the postoperative prognoses of advanced gastric cancer are still extremely poor. Clinical trials for a wide variety of chemotherapies before and /or after surgical operation have been carried out in a large number of hospitals to improve postoperative prognoses. However, even aggressive treatment through surgery or chemotherapy has not sufficiently prolonged the survival time, and there seems to be a limitation to surgical treatment for patients with distant metastasis of gastric cancer, such as liver metastasis and peritoneal dissemination.
1,2 Therefore, alternative novel therapeutic approaches to assist surgical treatment are urgently required for the improvement of the survival rate of advanced gastric cancer patients. Hepatocyte growth factor (HGF ) was originally identified and cloned as a potent mitogen for hepatocytes. 3, 4 It is a multi-functional molecule that exhibits mitogenic, motogenic, morphogenic, and angiogenic activities, leading to the invasion and metastasis of a variety of cancer cells. 5 -7 For example, Shibamoto et al. have reported that HGF stimulated both cell proliferation and migration of a c-Met-positive human gastric cancer cell line. 8 Furthermore, HGF is clinically recognized as a critical factor in many carcinomas, especially in gastric cancers. 9, 10 c-Met, the HGF receptor, is the proto-oncogene and is expressed in a wide variety of carcinoma cells, including gastric carcinoma cells. 11 As we reported previously, 12 c-Met overexpression was detected in 46.1% of gastric carcinoma cases and gene amplification was 10.2%. As the HGF-c-Met receptor system is involved in the malignant behavior of gastric cancer, HGF-c-Met coupling and subsequent activa-tion of c-Met may play a definitive role in invasion and metastasis of advanced gastric cancer.
Based on above notions, inhibition of c-Met receptor activation may possibly become a therapeutic strategy in gastric cancer. In this context, NK4 was isolated as a competitive antagonist for HGF. 13 It is composed of the N-terminal hairpin loop and four kringle domains in the -chain of HGF, and has been termed NK4. This molecule has the ability to bind specifically to the c-Met receptor without inducing any tyrosine phosphorylation of c-Met, resulting in prevention of HGF-mediated activities such as cancer cell proliferation and migration both in vitro and in vivo.
14,15 Thereafter, several basic research studies have revealed that the competitive inhibitory effects of NK4 on HGF-c-Met interactions resulted in suppression of malignant behavior in a wide variety of cancer cells including gallbladder, colon, breast, pancreas, prostate, ovary, and lung.
14 -21 However, to our knowledge, inhibitory and promising therapeutic effects of NK4 on gastric cancer have not been documented. As the cancer gene therapy is considered to be one of the promising strategies in the treatment of advanced gastric cancer, 22 we hypothesize that NK4 gene therapy may be effective and useful in the treatment of advanced gastric cancer patients.
The purpose of this study is to investigate the inhibitory effects of NK4 on cell proliferation in vitro, and tumor growth in vivo of a human gastric cancer cell line. Moreover, we assessed the efficacy of NK4 gene transduction by adenovirus-mediated gene transfer to establish a novel gene therapy for human gastric cancer.
Materials and methods

Materials
Recombinant human HGF was purified from the conditioned medium of Chinese hamster ovary cells ( CHO ) transfected with human HGF cDNA. 4, 23 Recombinant human NK4 was purified from the culture medium of CHO cells, which stably secrete human NK4, using three-step chromatographies ( manuscript in preparation ). The purity of NK4 was 96.4%, as determined by SDS-PAGE and protein staining. The purified NK4 protein was analyzed and determined to be negligible for endotoxin levels, using a Limulus Amebocyte Lysate kit (Bio Whittaker, Walkersville, MD, USA ), as described previously. 24 
Cells and culture conditions
The human gastric carcinoma cell line, TMK1, and the human embryonal kidney cell line, 293, were used. TMK1 cells were kindly provided by Dr Tahara ( First Department of Pathology, Hiroshima University School of Medicine, Hiroshima, Japan ) and 293 cells were obtained from the American Type Culture Collection (Manassas, VA, USA ). Cells were cultured in Dulbecco's modified Eagle's medium, nutrient mixture F-12, Ham 1:1 (DMEM /F12 ) supplemented with 10% heat-inactivated fetal bovine serum (FBS ), penicillin (100 units / ml ) and streptomycin sulfate (100 g/ml) unless otherwise specified. All media supplies were from Invitrogen, Carlsbad, CA, USA. All cultures were maintained at 378C in 5% carbon dioxide and 100% humidity.
Construction of the human NK4 expression plasmid and DNA transfection
The complete human NK4 cDNA was cloned into a pcDNA3 plasmid vector containing the neo-gene with a cytomegalovirus enhancer-promoter, and designated as pcDNA3 /NK4. DMRIE-C Reagent ( Invitrogen, Carlsbad, CA, USA ) is a liposome formulation of the cationic lipid DMRIE (1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide ) and cholesterol in membrane-filtered water. This was used to deliver foreign DNA into the cells. The transfection solution was prepared by adding 1 ml of DMEM /F12, containing 40 g of DMRIE-C Reagent, to the DNA solution of 1 ml DMEM/ F12 containing 10 g of pcDNA3 /NK4, mixing gently and incubating for 30 min at room temperature. TMK1 cells were then exposed to the 2 ml transfection mixture, and incubated at 378C in 5% carbon dioxide and 100% humidity for 4 hrs. After transfection, 8 ml of DMEM /F12 supplemented with 10% FBS was added to the 10 cm culture plates ( Iwaki glass, Tokyo, Japan ). Twenty-four hours later the medium was removed and replaced with DMEM /F12 containing geneticin (G-418 sulfate, 300 g /ml, Invitrogen, Carlsbad, CA, USA ). Twelve individual clones resistant to geneticin were selected and pooled. NK4-transfected TMK1 cells ( NK4 transfectants ) were maintained in complete culture medium containing geneticin to obtain stable transfectants.
RNA isolation and Northern blot analysis
NK4 mRNA expression in the NK4 stable transfectants was assessed by RNA blot analysis. Total RNA from the cultured transfectants was extracted using an ISOGENE kit ( Nippon Gene, Toyama, Japan ), and subjected to Northern blot analysis. Twenty g of each total RNA sample was electrophoresed in a 1% agarose-formaldehyde gel, then transferred to a nylon membrane ( Hybond N plus, Amersham, Buckinghamshire, UK ) in 10ÂSSC, and hybridized with 32 PdCTP-radiolabeled NK4 cDNA probe and 100 g /ml salmon testis DNA in Rapid-hyb buffer ( Amersham, Buckinghamshire, UK ) at 658C for 2 hrs. The cDNA probe was prepared using a DNA Labeling Kit (d-CTP ) (Pharmacia Biotech, Uppsala, Sweden ). Membranes were subsequently washed in 2ÂSSC and 0.1% SDS at room temperature for 20 min, then twice in 0.2ÂSSC and 0.1% SDS at 658C for 15 min. Autoradiographs were made using an imaging plate, and NK4 expression levels were analyzed densitometrically with a BAS 1000 Image Analyzer (Fuji Photo Film, Tokyo, Japan ). The membranes were rehybridized with a glyceraldehyde 3-phosphate dehydrogenase ( GAPDH ) cDNA probe to confirm that similar amounts of RNA were loaded and transferred from each sample.
Measurement of NK4 protein levels in transfectants
The NK4 protein levels in the transfectants were evaluated using a commercially available enzyme-linked immunosorbent assay ( ELISA ) ( IMMUNIS human HGF EIA, Institute of Immunology, Tokyo, Japan ). Dishes of subconfluent cells were washed twice with phosphatebuffered saline ( PBS ), scraped and collected. Cells were
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Experimental gastric cancer gene therapy treatment with NK4 S Hirao et al pelleted after centrifugation, resuspended in 10 ml PBS (-) and counted using a hemocytometer. Cells were then lysed in 500 l ice-cold lysis buffer containing 20 mM Tris-HCl ( pH 7.5), 2 mM EDTA, 20 mM KCl, 20% Glycerol, 1% Triton X-100, 0.02% Sodium azide, 0.4 mM phenylmethylsulfonyl fluoride and 100 mM iodoacetic acid for 15 min at 48C. The supernatants were collected by centrifugation and cell lysates were subjected to ELISA according to the manufacturer's protocol. The lowest detection limit of this assay is 0.10 ng/ ml and all the samples were assayed at least in duplicate.
Cell proliferation assays with the NK4 transfectant cell line Parent TMK1 cells ( P) and NK4 stable transfectant cells ( T11) were seeded and cultured in a 96-well plate at a density of 2500 cells per well. Cells were harvested in a final volume of 100 l DMEM /F12 medium containing 1% FBS and 10 ng /ml ( 110 pM ) HGF. The cells were cultured and at day 1, 3, 5, and 7, the number of viable cells was fixed with 5% glutaraldehyde and assessed by the crystal violet staining procedure. 25 
Animals
Five-week-old male BALB /cAnNCrj-nu nude mice ( Charles River Japan, Kanagawa, Japan ) were used in this study. Animals were housed in sterilized cages under light / dark cycle conditions (lights on from 8:00 A.M. to 8:00 P.M. ) at a temperature of 20-228C, and acclimated for a week. All the experimental procedures were reviewed and approved by the Animal Care and Use Committee of the Nara Medical University.
Inoculation of the NK4 transfectant in nude mice
Parent TMK1 cells ( P) and NK4 stable transfectant cells ( T11) were injected into the flanks of athymic BALB / c nude mice. P cells and T11 cells were taken from continuous culture and resuspended in phosphate-buffered saline ( PBS ) without fetal bovine serum ( FBS ) for inoculation. The final concentration of 1Â10 6 viable cells was suspended in 100 l of PBS and inoculated subcutaneously (s.c. ) into the flanks of 5-week-old male BALB / c nude mice. Four animals were used for each group and all injections were made using a 1 ml syringe with a 26 gauge needle. Tumor size was measured twice weekly with the tumor volume calculated as [ length (mm )Âwidth (mm ) 2 ]/ 2, and tumor growth was evaluated by the tumor volume. The animals were sacrificed on day 31 after the initial inoculation. The s.c. tumors were excised and the NK4 protein levels were measured using the human HGF ELISA kit described previously. The tissue extracts were prepared according to the manufacturer's protocol and the protein levels of human recombinant NK4 were determined at least in duplicate.
Preparation of recombinant adenovirus vectors
The replication-deficient adenovirus vectors used in this study are E1a-, partially E1b-, and partially E3 deleted vectors based on the human adenovirus type 5. Briefly, an adenovirus vector was generated by homologous recombination of the pJM17 plasmid ( Microbix Biosystems, Toronto, Canada) and the shuttle plasmid vector pCMV.SV2 +. 26 The resulting vector contains an expression cassette using the cytomegalovirus early promoter /enhancer, followed by the 1.4 kb human NK4 cDNA ( corresponding to 1 Met to 473 Val of HGF -chain including signal sequence ( 1 Met to 31 Gly) as an N-terminal peptide of HGF ) and a polyadenylation signal. The resultant recombinant AdCMV.NK4 vector was propagated in 293 cells ( adenovirus E1a-transformed human embryonal kidney cells ), and purified by cesium chloride density gradient ultra-centrifugation. 27 Concentrated virus solutions were stored at À 808C and the titers of viral stocks were determined by plaque assays using the 293 cells as described elsewhere. 27, 28 The adenovirus containing the Escherichia coli LacZ gene ( AdCMV.LacZ ) driven by the cytomegalovirus promoter was used as a control.
Adenovirus-mediated LacZ expression determined by X-gal staining in vitro
LacZ gene expression in TMK1 cells was determined by the AdCMV.LacZ transduction assay. 25 During the exponential growth phase, TMK1 cells were seeded in 24-well culture plates at a density of 5Â10 4 cells per well. Cells were harvested in the final volume of 1 ml DMEM /F12 medium containing 10% FBS. After 24 hrs incubation, the culture medium was aspirated and the AdCMV.LacZ virus solution was distributed over the cell monolayer in various amounts, from 0 to 100 multiplicity of infection (MOI ). After another 24 hrs of culture, the cells were stained with 5-bromo4chloro-3-indolyl--D-galactopyranoside (X-gal) and LacZ expression was evaluated. 27, 28 The virus dose that exhibited satisfactory transduction without severe cell toxicity in TMK1 cells was determined, resulting in a MOI of 10 (data not shown). Therefore, we used each adenovirus vector at a MOI of 10 for the in vitro studies.
In vitro cell proliferation assays of AdCMV.NK4 infected cells
The effect of AdCMV.NK4 infection on TMK1 cells was evaluated by in vitro proliferation assays. Cells were plated and cultured in a 96-well plate at a density of 2500 cells per well and divided into three groups: no virus group (control ), AdCMV.LacZ group, or AdCMV.NK4-infected group. After 24 hrs incubation, cells were infected with the recombinant adenoviruses; AdCMV.LacZ or AdCMV.NK4, at a MOI of 10 in a final volume of 100 l DMEM/ F12 medium containing 1% FBS and 10 ng /ml ( 110 pM ) HGF. The cells in each group were harvested at 378C and at days 1, 3, 5, and 7, the number of viable cells was fixed with 5% glutaraldehyde and counted by the crystal violet staining procedure.
In vitro tumor treatment with AdCMV.NK4
To examine the effect of AdCMV.NK4 on tumor growth in vivo, adenoviral vectors were injected into s.c. tumors of athymic nude mice. TMK1 cells (1Â10 6 ) were suspended in 100 l of phosphate-buffered saline (PBS ), and inoculated subcutaneously into the flanks of 5-week-old male BALB / c mice. Seven days after the inoculation, the mice with established tumors were randomized into three treatment groups: PBS group (control ), AdCMV.LacZ group, or AdCMV.NK4-treated group (n =6 in each group ). Subsequently, 100 l PBS alone, or a suspension of adenovirus (1Â10 9 plaque forming units (pfu )) in 100 l of PBS, was administered directly into the tumors of the mice in each group daily for 5 days. All injections were made using a 1 ml syringe with a 26 gauge needle. Tumor size was measured twice weekly using a dial caliper with the tumor volume calculated as [ length ( mm )Âwidth (mm ) 2 ]/2, and tumor growth was evaluated by the tumor volume. The animals were sacrificed on day 32 after the initial inoculation of TMK1 cells. Seven days after administration, a mouse from each group was picked at random to measure the NK4 protein levels in the s.c. tumors. The tumors were excised and the NK4 protein levels were measured using the human HGF ELISA kit described previously. The protein levels of human recombinant NK4 were determined at least in duplicate.
Statistical analysis
Data analysis of the differences between the experimental groups was calculated by the one-way ANOVA throughout the study and considered to be statistically significant at P < .05.
Results
Selection of NK4-transfected TMK1 cells
In this study, we used a gastric cancer cell line TMK1, which expresses c-Met, the HGF receptor, 29 but scarcely secretes HGF itself ( data not shown). To clarify the function of NK4, we transferred NK4 expressing plasmid into TMK1 and investigated the endogenous effects of NK4 on both in vitro and in vivo cell growth. First, the expression of NK4 in NK4-transfected TMK1 cells was analyzed by Northern blot analysis ( Fig 1A ) , ELISA analysis (Fig 1B ) , and Western blot analysis. Northern blot analysis revealed a high level of NK4 mRNA expression in one line of NK4-transfected TMK1 cells (T11 ) and low levels of expression in two other lines, T12 and T14. No expression was detected in parent TMK1 cells (P ) and any other NK4-transfected TMK1 cells including T13 cells. ELISA analysis revealed the presence of NK4 protein in T11, T12 and T14 cells (380 ng /1Â10 6 cells, 28.7 ng/ 1Â10 6 cells, and 20.0 ng/ 1Â10 6 cells, respectively ), while it was below the lowest detectable limit for P and T13 cells. Furthermore, P cells and T11 cells were subjected to Western blot analysis utilizing a polyclonal antibody against human HGF prepared from the serum of a rabbit immunized with human recombinant HGF.
14 NK4 expression was detected in T11 cells at the position corresponding to a molecular mass of 67 kDa, while no expression was detected in P cells (data not shown ). Therefore, the two cell lines, P cells and T11 cells, were chosen for further studies.
Proliferation rate of the NK4 transfectant in vitro
Proliferation assays were performed to determine whether the endogenous NK4 could inhibit cell proliferation of the Absorbance at 590 nm 
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Experimental gastric cancer gene therapy treatment with NK4 S Hirao et al was stimulated by 2.5-fold on the day 7 (Fig 2 ) . On the other hand, the proliferation of T11 cells was significantly inhibited compared with the parent TMK1 cells (P ) in the presence of 10 ng /mg HGF ( Fig 2) . The growth inhibition rate of T11 cells compared to P cells on the day 7 was 75% ( P <.01 ).
Growth rate and the NK4 protein levels of NK4 transfectant in vivo
The effect of endogenous NK4 on tumor growth was also studied in nude mice. Parent TMK1 cells (P ) and NK4 transfectant cells (T11 ) were inoculated subcutaneously ( s.c. ) into the flanks of athymic nude mice (n =4 in each group ). The tumors of P cells were observed to grow more rapidly than T11 cells ( Fig 3A ) . The tumor volume of T11 cells was significantly different from that of the other group from day 10 until the end of the experiment (day 31; 78% inhibition, P < .01). NK4 protein levels extracted from the s.c. tumors of P cells and T11 cells on day 31 were 0.06 ng / mg and 31.4 ng /mg, respectively, as determined by the human HGF ELISA ( Fig 3B ) . Besides P and T11 cells, we have also examined the s.c. tumors of T12, T13, and T14 cells. The tumor volume of T12, T13, and T14 cells was not significantly different from that of the P cells (data not shown ). There were no accidental deaths or illnesses of the mice and the differences in body weight of each group were less than 20% throughout this study.
The effect of AdCMV.NK4 on the in vitro cell proliferation of TMK1
We next analyzed the effect of exogenous NK4 gene delivery by adenovirus on cell proliferation. Proliferation assays were performed to determine whether AdCMV.NK4 could inhibit the growth of TMK1 cells. First, with the addition of 10 ng / mg (110 pM ) HGF, proliferation of TMK1 cells was stimulated by 2.7-fold on the day 7 ( Fig 4) . Then the cell proliferation was analyzed in three different groups: no virus group ( control ), the AdCMV.LacZ group, or the AdCMV.NK4 infected group in the presence of 10 ng /mg HGF. The growth of AdCMV.NK4 infected TMK1 cells was significantly inhibited compared with non-infected or AdCMV.LacZ infected cells (Fig 4 ) . The growth inhibition in AdCMV.LacZ-group at day 5 is probably due to the mild toxicity of adenovirus, and there was no significant difference between the AdCMV.LacZ and the non-infected group at day 7; P= .24. The growth inhibition rate of AdCMV.NK4 infected cells compared to non-infected cells on the day 7 after infection was 65% ( P< .01 ).
The effect of AdCMV.NK4 on the in vivo tumor growth of transplanted TMK1 cells
The exogenous gene transfer by adenovirus was also studied in a tumor-bearing BALB /c nude mouse system. We sought 
Experimental gastric cancer gene therapy treatment with NK4 S Hirao et al to determine whether AdCMV.NK4 could suppress the malignant behavior of TMK1 cells in nude mice. Seven days following the inoculation of TMK1 cells into the flanks of nude mice, tumors were approximately 3 to 5 mm in diameter, and the mice were randomized into three treatment groups (n = 6 in each group ). After AdCMV.NK4 treatment the tumor showed no tendency to enlarge until day 21. Although tumor growth was observed gradually from day 25, the tumor volume following treatment with AdCMV.NK4 was significantly inhibited compared with that of the PBS treated group from day 14 until the end of the experiment (day 32; 71% inhibition, P <.01 ) (Fig 5A ) . The AdCMV.LacZ treated tumors showed a slight growth inhibition in the early phase. However, tumor volume was not significantly different compared to that of the PBS treated group from day 25 until the end of the study ( day 32; 14% inhibition, P= .06). Measurement of NK4 protein levels in treated tumors was also evaluated using the human HGF ELISA. Seven days after treatment, a mouse from each group was chosen at random and protein was extracted from the tumors of the PBS-group, the AdCMV.LacZ -group, and the AdCMV.NK4 treated group. NK4 protein concentrations were 0.05 ng/ mg, 0.01 ng /mg, and 7.36 ng /mg, respectively ( Fig 5B ) . NK4 protein levels in extracted tumors at the day 32 were undetectable in none of the groups. Throughout these experiments there were no significant differences in body weight and no illnesses nor accidental deaths of the mice in any treatment group.
Discussion
Cancer gene therapy is now being widely investigated for the future clinical treatment of advanced cancers. In the present study, the effects of NK4 on cell proliferation of the human gastric cancer cell line, TMK1, and tumor growth of xenografted subcutaneous tumors in nude mice were evaluated. We first examined the effects of endogenous NK4 on cell growth of the NK4-transfected TMK1 cells ( T11). It was shown that NK4 derived from the transfectant ( T11) significantly inhibited cell proliferation ( Fig 2 ) . Moreover, tumor growth of transplanted T11 cells in nude mice was significantly suppressed (Fig 3A ) . These results clearly indicated the remarkable antagonistic effect of endogenous NK4 towards HGF. Furthermore, the effect of exogenous NK4 on cell growth of TMK1 using a NK4 expressing adenovirus vector was examined, considering the possibility of NK4 gene therapy treatment for gastric cancer patients. Cell proliferation experiments showed that AdCMV.NK4 infection led to significant growth inhibition of TMK1 cells ( Fig 4 ) . In addition, in vivo treatment with AdCMV.NK4 showed significant growth suppression of TMK1-xenografted s.c. tumors in nude mice compared with the control group (Fig 5A ) . These results demonstrated that adenoviral-mediated exogenous NK4 gene delivery induced a marked growth suppression of gastric cancer cells. Since the tumors of AdCMV.NK4 treated group started to enlarge from day 25, repeated viral injection might be effective to maintain a high level of NK4 protein expression, leading to persistent growth inhibition of the tumors. As for the in vitro experiments, we supplemented medium with additional human recombinant HGF to determine the inhibitory effect of NK4. The reason is that the antagonistic effect of NK4 on tumor cells is in a competitive manner with 
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Experimental gastric cancer gene therapy treatment with NK4 S Hirao et al HGF and should be evaluated under conditions with HGF, which is a stromal-derived multi-potent growth factor and mainly produced from fibroblasts surrounding the tumor. 6 Consequently we assessed cell proliferation assays in medium including 10 ng /mg HGF, and significant growth inhibition was observed in both NK4-transfected cells and TMK1 cells infected with AdCMV.NK4. NK4 binds to the c-Met receptor and competitively antagonizes HGF-induced tyrosine phosphorylation, resulting in inhibition of tumor progression induced by HGF.
Suppressive effect of NK4 on gastric cancer cell line is at least because of its antagonistic factor toward HGF. However anti-angiogenesis factor of NK4 may also be involved in the growth inhibition of the tumors. NK4 has inhibitory effect of angiogenesis driven by basic fibroblast growth factor ( bFGF ), vascular endothelial growth factor ( VEGF ), as well as HGF. 21, 24, 30 Considering these two-way inhibitory effects, gene therapy using NK4 seems to be an ideal potential therapy for treatment of patients with advanced gastric cancer. Basic research toward gene therapy using anti-angiogenic substances such as angiostatin and endostatin has been widely reported. 31 -33 Suppression of angiogenesis leads to the extended tumor dormancy rather than the drastic killing of cancer cells. Therefore, in terms of tumor dormancy, cancer gene therapy using NK4 may also be an attractive new approach for treatment of advanced cancer patients. Inhibitory effects of NK4 are achieved by both increased apoptosis and decreased proliferation of tumor cells.
14 Inhibition of tumor angiogenesis results in tumor suppression through the induction of apoptosis of tumor cells. 33 Since anticancer chemotherapeutic drugs also induce apoptosis of tumor cells, NK4 gene therapy in combination with chemotherapy could be expected to enhance the suppressive effects on tumors of gastric cancer.
From a clinical point of view, patients with advanced gastric cancer might be ideal candidates for NK4 gene therapy, because NK4 has a powerful potential to suppress tumor metastatic behavior and NK4-mediated improvement could be expected to extend survival of the patients. For cancer gene therapy, typical replication-deficient adenovirus vectors are used at present situation. However, basic research studies have been reported to overcome some of the problems in gene therapy such as specific targeting with less damage of other normal cells and high efficacy of gene transfer. 34 With the advancement of recombinant DNA techniques, a tumor-specific gene can be expressed by the use of promoter elements of genes usually transcribed by tumors. Lan et al. reported selective gene expression and therapy mediated by an adenoviral vector with a CEA ( carcinoembryonic antigen ) promoter for the human CEAproducing gastric carcinoma. 34 CEA is often expressed at high levels in gastrointestinal malignancies, including gastric cancer and is widely recognized as a tumor marker. Although CEA is also expressed in some normal tissues, the amount expressed is different compared with malignant tissues. The CEA promoter-controlled adenovirus vector made it possible for the harbored gene to be expressed selectively in cancer cells.
In conclusion, our studies demonstrated that NK4 inhibited cell proliferation of a gastric cancer cell line. Furthermore, NK4 was also able to suppress the tumor volume of cancer cells in nude mice. Therefore, NK4 is a promising therapeutic agent for the suppression of malignant behavior in tumors and its gene delivery may be a new approach to treating patients with advanced gastric cancer.
